In Vivo Research Protocols Published preclinical protocols for Epithalon in rodent aging models typically employ subcutaneous administration at doses of 0.11.0 g per animal per day, administered in cycles (commonly 10 consecutive days, repeated at intervals)
However, Ozempic (another form of semaglutide) and Mounjaro (tirzepatide) are only FDA approved for type 2 diabetes, not weight loss
Medications like Ozempic can also lead to unintended facial volume loss, often referred to as "Ozempic face." While effective in reducing body fat, it doesnt target specific areas, meaning you lose fat from your body and face
Body Weight Research The STEP 1 trial, a randomized placebo-controlled study in adults with overweight or obesity without diabetes, reported substantial and sustained mean weight reduction of approximately 14.9% with once-weekly semaglutide plus lifestyle intervention, with 86% of participants achieving at least 5% reduction one of the most influential datasets in metabolic research 3
Circ Res 114:17881803